have shown a high, immediate risk of thrombosis after the procedure, likely related to the surgery and the impact of cardiopulmonary bypass itself (10) . There also appears to be an increasing risk over the long term after Fontan (11) , culminating in a substantial proportion of late-term (Ͼ10 years) mortality in this population being associated with thromboembolic complications (7, 12, 13) .
Multiple studies have explored the effectiveness of thromboprophylaxis strategies in this population (3, 14) ; consensus has yet to be achieved on the matter. This has led to institutional variation in practices, with some centers using low-intensity antiplatelet-based therapy and others using highintensity anticoagulation-based therapy (15) . Therapy is selected on the basis of physician discretion, with decision making being driven by weighing the perceived thrombosis risk for a given patient against the inherent risks of long-term anticoagulation (14) . In this context, an evidence-based stratification of patients according to thrombosis risk would be a useful tool in selecting the intensity of thromboprophylaxis strategy warranted in these patients.
Few risk factors have been confirmed from observational studies, including the presence of bilateral bidirectional cavopulmonary shunts, a blind-ended pulmonary artery stump, a hypoplastic chamber with stasis of flow, and previous thrombosis (2, 16 ). An atriopulmonary or Kawashima Fontan connection type, presence of thrombogenic material, dilated atrium, arrhythmias, ventricular dysfunction, patent fenestration, and protein-losing enteropathy have all also been hypothesized as potential risk factors in this population (7, 17) . Increased presence of thrombophilic risk factors have been described, with uncertain clinical meaning, both before and after Fontan (18 -23) . As a secondary analysis of a prospective, multicenter randomized clinical trial of thromboprophylaxis strategies for the first 2 years after the Fontan procedure (24) , we sought to identify factors associated with increased risk of thrombosis in this population.
Methods
This is a secondary analysis of a previously published randomized controlled trial. Complete details of study intervention and trial results have been previously reported (24) . Study subjects. Patients were recruited between 1998 and 2003 from 6 institutions (242 patients screened, 208 eligible, 111 enrolled and randomized). All patients who underwent Fontan procedure at participating institutions were eligible for inclusion in the trial. Exclusion criteria were a recognized indication for long-term anticoagulation; patient characteristics increasing the risk of hemorrhagic complications; known contraindication for heparin, warfarin, or acetylsalicylic acid (ASA); and the inability to supervise therapy because of social or geographic circumstances. Randomization and study intervention. Randomization (centrally performed but stratified by center) was performed immediately after completion of the Fontan procedure. Subjects were randomized to either warfarin therapy (0.1 mg/kg titration to achieve and international normalized ratio (INR) of 2 to 3 with heparin lead-in) or ASA (5 mg/kg/day) for a 2-year period after the procedure. INR monitoring was prescribed to be performed at least every 2 to 3 weeks for stable patients and more frequently for patients with dosing challenges. Proportion of INR measurement within the target range was calibrated to risk and then included in risk factor analyses. On the basis of this analysis, we defined controlled warfarin therapy as Ͼ30% of INR measurements within the target range (INR 2 to 3). Measurements. Demographics, underlying cardiac anatomy, previous interventions and complications, and previous and current medical therapy were abstracted for each patient from their respective medical records, including data regarding the Fontan procedure and post-operative complications. Patients were asked to undergo clinical evaluation at 3, 6, 12, 18, and 24 months after randomization and whenever it was clinically indicated regardless of whether they were still taking their assigned study medication and/or had reached a study endpoint. Thrombotic events (venous or arterial) were the study primary endpoint. Thrombosis was defined as the appearance of a space-occupying lesion on ultrasound within the cardiovascular system (mild laminar thickening of the internal surface of the Fontan pathway was not included) or the occurrence of a clinical event known to be strongly associated with thrombus (stroke, pulmonary embolism). Thrombosis with clinical presentation or clinical events known to be strongly associated with thrombus (cardioembolic stroke, pulmonary embolism), were captured for all patients, regardless of whether planned echocardiography or TEE were performed. Transthoracic echocardiography and TEE were sought twice at 3 and 24 months post-Fontan procedure. An independent central adjudication committee reviewed all clinically driven and routine echocardiograms. All thrombosis and major adverse clinical events were adjudicated by an expert panel. Statistics. Data are presented as mean Ϯ SD, median with minimum and maximum value, and frequency, as appropriate. Time-related risk of thrombosis was modeled in parametric hazard regression model (maximum likelihood method for parameter estimation), which allows for risk of thrombosis to be divided in up to 3 distinct phases of risk, although only an early and a late phase were present in this study. Because of the limited number of events, risk hazard analysis was performed assuming a single phase of risk. A stepwise variable selection strategy was used (forward entry, only variables with univariable p values Ͻ0.10 eligible for entry) to create a multivariable parametric survival regression model. All analyses presented in this study combined McCrindle et al. January 22, 2013:346-53 Thrombotic Complications After Fontan both groups. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, North Carolina).
Results

Study population.
A total of 111 patients (64% male, average age at Fontan 4.8 Ϯ 2.8 years) were enrolled. Primary diagnoses were tricuspid atresia (n ϭ 21, 19%), double inlet left ventricle (n ϭ 21, 19%), double outlet right ventricle (n ϭ 12, 11%), pulmonary atresia with intact ventricular septum (n ϭ 6, 5%), unbalanced atrioventricular septal defect (n ϭ 10, 9%), hypoplastic left heart (n ϭ 17, 15%), and other/multiple anomalies (n ϭ 24, 22%). The majority of patients had previous cardiac catheterization (n ϭ 63, 56%), and 24 (22%) had a previous Norwood operation. A total of 72% of patients had a previous bidirectional cavopulmonary shunt, 14% had a bilateral cavopulmonary shunt, and 14% had undergone the DamusKaye-Stansel procedure. The majority of patients had a Fontan procedure utilizing an extracardiac conduit (n ϭ 95, 85%) with GORE-TEX baffle (n ϭ 81, 73%) and fenestration (n ϭ 69, 62%).
Original trial results. The original trial found no difference in risk of thrombosis between patients randomized to warfarin (n ϭ 54) versus those randomized to ASA (n ϭ 57); hazard ratio [HR]: 1.35, 95% confidence interval [CI]: 0.62 to 3.00, p ϭ 0.45) at the 2 years study endpoint (24) . Patient characteristics and compliance with study procedures and measurements were similar between both experimental groups (24) . Because of the lack of differences, all analyses presented in this study combined both groups. Study follow-up and compliance with study procedures.
Of the 111 patients enrolled in this study, 3 patients died or were withdrawn from the study prior to study end or reaching primary outcomes. A further 3 patients died or were withdrawn from the study after reaching the study primary outcome. All other patients attended the final study visit within 30 months of enrollment. Complete accrual of clinical events was obtained, 81% of patients underwent at least 1 TEE (69% having the 3-month TEE, 61% having the 24-month TEE) and 48% having both protocol TEEs. Prevalence of thrombosis. At 2.5 years after randomization, time-related freedom from thrombosis was 69% (all venous, no arterial events), with 28% of thrombosis presenting with clinical signs or events. Time-related risk of thrombosis was divided in 2 distinct phases-an early phase of risk spanning the first 6 months after the Fontan procedure, followed by late phase spanning the subsequent 2 years (Fig. 1 ). The risk of thrombosis associated with a clinical presentation was highest immediately following Fontan surgery, but persisted with a gradual increase throughout the study period.
Compliance with study drug assignment and protocol. Early discontinuations of study drug were more frequent in the warfarin group (19% vs. 9%), with patients assigned to ASA therapy spending 92% of expected study days on the study drug compared to 84% for patients assigned to warfarin (p ϭ 0.02). A total of 2,166 INR monitoring values were available in 45 patients (INR monitoring results were not available for 9 patients), of which 41% were below target range (Ͻ2), 44% were within target range, and 15% were above target range (Ͼ3 Regarding freedom from (A) and hazard of (B) thrombosis, all patients are included from study randomization up to first thrombotic event, study withdrawal, or end of study, no censoring for drug discontinuation. Dotted lines represent 95% confidence interval. A high early-phase hazard is present followed by a lower, but increasing, hazard of thrombosis in the late phase. 
Discussion
The current study found that there is a substantial immediate risk of thrombosis which diminishes but persists over the first 2.5 years after Fontan procedure. Overall timerelated risk of thrombosis as found in this study was somewhat different from that reported before in populationbased observational studies (3, 11, 17) , which have showed a ϳ10% surgery-related thrombosis prevalence and then an ongoing risk over time. Prevalence of surgery-related thrombosis has previously been reported (10) at approximately ϳ10% for low-risk surgeries such as the Fontan procedure. Because patients with surgery-related thrombosis are often required to be on anticoagulation for an extended period of time, these patients would not have been eligible for this study. Our rate of thrombosis after the immediate high-risk surgical period in enrolled patients is consistent with previously reported studies (11) . Of note, all thromboses were found in the venous system. This is consistent with previous reports where thrombosis is typically located within both pulmonary and systemic venous systems (2, 25) . However, no thromboembolic event, such as central nervous system (CNS) or pulmonary or coronary artery embolism, were noted in our subjects. There was no routine CNS surveillance, so clinically silent events may have been missed. Previous studies have reported the incidence of stroke to be as high as 19% post-Fontan (2,7,26 -28) .
Factors associated with thrombosis in this population included anatomical characteristics, pre-operative clinical status and post-operative outcomes, and anticoagulation management. Anatomical factors disturbing laminar blood flow are known to increase the risk of thrombosis in children with congenital heart disease by creating physiological dead ends and areas of sluggish flow promoting thrombus formation (2, 16) . Other identified risk factors have been associated with increased propensity to clot, either by promoting platelet activation through inflammation (low oxygen saturation), impaired metabolism of coagulation proteins secondary to liver dysfunction (low bilirubin) (29 -31) , and/or damage to vascular walls (central venous lines). Most of these risk factors have been reported previously, both in the Fontan population and in other populations with congenital heart disease (10). Of particular importance is the increased risk of thrombosis associated with prolonged use of central venous lines (10) . Aggressive strategies for early line removal and interventions aimed at reducing the prevalence of line-related thrombosis might have an important impact on the occurrence of early thrombosis in this population.
The most important finding of this study is the decreased risk of thrombosis associated with properly controlled warfarin therapy or ASA compared with warfarin therapy with Ͻ30% of INR monitoring within the target range. Difficulties in controlling warfarin therapy are well documented in pediatric patients (32, 33) . Individual response to warfarin varies between patients on the basis of physiological and genetic factors. Furthermore, warfarin dosing is known to be affected by a multitude of drug and food interactions. Previous studies have shown minimal anticoagulation activity with INR Ͻ2, and almost nonexistent anticoagulation activity when INR falls below 1.5 (34) .
Our study showed an increased risk of thrombosis for patients with poorly controlled warfarin therapy. Clinically, this finding has multiple implications; it may provide an explanation why previous studies have found inconsistent results regarding the efficacy of strategies for thromboprophylaxis in Fontan patients. The earliest nonrandomized comparison reported better event-free survival for patients receiving warfarin versus no anticoagulation (3). Three small case series with few events (2 studies, n ϭ 4; 1 study, n ϭ 10) concluded that there was no influence of anticoagulation (6, 28, 35) . The trial on which this study is based found no differences between ASA and warfarin (24) . Finally, a recent single-center observational study of thromboprophylaxis in single ventricle patients, in which warfarin was favored for the majority of patients, found that warfarin-based thromboprophylaxis was associated with a significant reduction of thrombosis risk compared with no thromboprophylaxis and to ASA-based thromboprophylaxis (11) .
The other important clinical consideration raised by these results regards the risk-benefit ratio for these patients. Since risk reduction for thrombosis is minimal in patients with poorly controlled warfarin therapy, the risk of anticoagulation becomes unwarranted. Future studies should try to determine patient characteristics are associated with diffi- 
culties achieving consistent anticoagulation with warfarin. The thromboprophylaxis strategy in these patients should be carefully selected taking this information into account.
Patients who have started warfarin-based thromboprophylaxis but who are unable to maintain adequate INR levels may be better off receiving ASA therapy alone. New oral anticoagulants, which have been shown in adult trials to be noninferior regarding efficacy while being more stable, easier to dose, and overall safer than warfarin (36 -39) , might be a solution for this population, however, as their safety in children is undetermined, future comparative trials would be required (40) . Study limitations. This study must be viewed in light of some limitations. Children in our study did not undergo CNS imaging, and clinically silent events may have been missed. Not all patients had both TEEs as stipulated in the protocol. Therefore, some asymptomatic thrombi might not have been identified. Because of the limited number of events available for analysis we had to collapse the 2 identified phases of risk (early and late) into 1 and perform McCrindle et al. January 22, 2013:346-53 Thrombotic Complications After Fontan a classic single-phase risk factor analysis that might not be optimal. Additionally, details of INR monitoring were not available for all patients included in the warfarin group; therefore, our classification of controlled vs. uncontrolled warfarin applied only to a subset of patients. Finally, although our study outlines the importance of achieving target levels of anticoagulation with warfarin, the determination of whether a given patient is likely to have warfarin dosing difficulties requires a lengthy exposure to warfarin and consequently a lengthy increased-risk period for thrombosis. The results of this post hoc secondary analysis must be viewed as hypothesis generating, although they also suggest superiority of well-controlled warfarin over ASA, which is in contrast to the primary intention to treat analysis reported for the clinical trial (24) . Considering the fact that we could not identify factors associated with poorly controlled warfarin therapy in these patients, ASA might be the best current strategy to prevent thrombosis for the overall population. Future studies, including both laboratory assessments and genetic evaluations, may be helpful to determine which patients are at increased likelihood of having problems with warfarin dosing.
Conclusions
This study demonstrated that patients with Fontan physiology have a high and ongoing risk of thrombosis, which is highest in the immediate perioperative period, followed by a lower chronic risk that may gradually increase with longer-term follow-up. Underlying physiology and postoperative clinical status were associated with increased risk of thrombosis. This study also outlined the importance of achieving minimum therapeutic targets when using warfarin for thromboprophylaxis. Future studies should focus on identifying factors associated with failure of warfarin therapy and evaluating the effectiveness and safety of new oral anticoagulants.
Figure 2 Freedom From Thrombosis Over Time Stratified by Thromboprophylaxis Choice and Effectiveness
All patients included from study randomization up to first thrombotic event, study withdrawal, or end of study, no censoring for drug discontinuation. Controlled warfarin was defined as Ͼ30% of international normalized ratio (INR) within target over the study period. Patients on warfarin who consistently achieved target INR levels Ͼ30% of the time or those on acetylsalicylic acid had a 3.5-fold decrease in risk of thrombosis compared patients who often failed to meet target INR level (hazard ratio: 3.53, 95% confidence interval: 1.35 to 9.20, p ϭ 0.01), and difference in risk between controlled warfarin and ASA was not statistically significant (hazard ratio: 0.34, 95% confidence interval: 0.10 to 1.13, p ϭ 0.08). 
